Results 91 to 100 of about 88,063 (262)

The kidney transcriptome and proteome defined by transcriptomics and antibody-based profiling.

open access: yesPLoS ONE, 2014
To understand renal functions and disease, it is important to define the molecular constituents of the various compartments of the kidney. Here, we used comparative transcriptomic analysis of all major organs and tissues in the human body, in combination
Masato Habuka   +9 more
doaj   +1 more source

Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE‐Mediated Renal Drug‐Drug Interactions in Healthy Volunteers

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Regulatory agencies request the assessment of the potential of new drugs to cause transporter‐mediated drug‐drug interactions (DDI). This assessment can be improved by integrating endogenous biomarkers during drug development. Regarding the renal excretion of drugs such as metformin, the organic cation transporter (OCT) 2 and multidrug and toxin ...
Jana Picurová   +5 more
wiley   +1 more source

The Antidiabetic Agent Sodium Tungstate Induces Abnormal Glycogen Accumulation in Renal Proximal Tubules from Diabetic IRS2-Knockout Mice

open access: yesJournal of Diabetes Research, 2018
The kidney is an insulin-sensitive organ involved in glucose homeostasis. One major effect of insulin is to induce glycogen storage in the liver and muscle.
Romina Bertinat   +7 more
doaj   +1 more source

Zebrafish inversin mutants develop scoliosis in the absence of laterality defects

open access: yesDevelopmental Dynamics, EarlyView.
Abstract Background Human mutations in INVERSIN are associated with nephronophthisis, variable penetrance of situs inversus and congenital heart disease. Inversin has been shown to localize to cilia and many of the patient phenotypes are attributed to disrupted cilia function.
Christopher J. Derrick   +3 more
wiley   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou   +7 more
wiley   +1 more source

Progress in microelectrode techniques for kidney tubules.

open access: yesThe Yale journal of biology and medicine, 1972
Although microelectrode measurements have caused a good deal of confusion in the investigation of renal electrolyte transport (for literature see Ref.4), we cannot do without them. Knowledge of the electrical potential steps, which the ions have to pass during their reabsorption, is indispensable for understanding the transport mechanisms involved ...
openaire   +2 more sources

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li   +12 more
wiley   +1 more source

Short‐term clinical responses in horses and ponies treated with canagliflozin: A clinical field study

open access: yesEquine Veterinary Journal, EarlyView.
Abstract Background Treatment with the sodium‐glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin in insulin dysregulated (ID) horses has shown promising results in randomised clinical trials. Larger field studies are needed to further evaluate treatment responses and potential adverse effects under real‐world conditions.
Moa Hällbom   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy